These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

293 related articles for article (PubMed ID: 18491995)

  • 1. Teduglutide in intestinal adaptation and repair: light at the end of the tunnel.
    Mardini HE; de Villiers WJ
    Expert Opin Investig Drugs; 2008 Jun; 17(6):945-51. PubMed ID: 18491995
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Teduglutide (ALX-0600), a dipeptidyl peptidase IV resistant glucagon-like peptide 2 analogue, improves intestinal function in short bowel syndrome patients.
    Jeppesen PB; Sanguinetti EL; Buchman A; Howard L; Scolapio JS; Ziegler TR; Gregory J; Tappenden KA; Holst J; Mortensen PB
    Gut; 2005 Sep; 54(9):1224-31. PubMed ID: 16099790
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Acute effects of the glucagon-like peptide 2 analogue, teduglutide, on intestinal adaptation in short bowel syndrome.
    Thymann T; Stoll B; Mecklenburg L; Burrin DG; Vegge A; Qvist N; Eriksen T; Jeppesen PB; Sangild PT
    J Pediatr Gastroenterol Nutr; 2014 Jun; 58(6):694-702. PubMed ID: 24399211
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Teduglutide, a glucagon-like peptide-2 analog for the treatment of gastrointestinal diseases, including short bowel syndrome.
    Yazbeck R
    Curr Opin Mol Ther; 2010 Dec; 12(6):798-809. PubMed ID: 21154171
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Short bowel syndrome: the role of GLP-2 on improving outcome.
    Wallis K; Walters JR; Gabe S
    Curr Opin Clin Nutr Metab Care; 2009 Sep; 12(5):526-32. PubMed ID: 19474717
    [TBL] [Abstract][Full Text] [Related]  

  • 6. New approaches to the treatments of short bowel syndrome-associated intestinal failure.
    Jeppesen PB
    Curr Opin Gastroenterol; 2014 Mar; 30(2):182-8. PubMed ID: 24406477
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pharmacologic options for intestinal rehabilitation in patients with short bowel syndrome.
    Jeppesen PB
    JPEN J Parenter Enteral Nutr; 2014 May; 38(1 Suppl):45S-52S. PubMed ID: 24615689
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Teduglutide for the treatment of short bowel syndrome.
    Ferrone M; Scolapio JS
    Ann Pharmacother; 2006 Jun; 40(6):1105-9. PubMed ID: 16705029
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Growth factors in short-bowel syndrome patients.
    Jeppesen PB
    Gastroenterol Clin North Am; 2007 Mar; 36(1):109-21, vii. PubMed ID: 17472878
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Teduglutide for pediatric short bowel syndrome patients.
    Rosete BE; Wendel D; Horslen SP
    Expert Rev Gastroenterol Hepatol; 2021 Jul; 15(7):727-733. PubMed ID: 33798402
    [No Abstract]   [Full Text] [Related]  

  • 11. Quality of life in patients with short bowel syndrome treated with the new glucagon-like peptide-2 analogue teduglutide--analyses from a randomised, placebo-controlled study.
    Jeppesen PB; Pertkiewicz M; Forbes A; Pironi L; Gabe SM; Joly F; Messing B; Loth S; Youssef NN; Heinze H; Berghöfer P
    Clin Nutr; 2013 Oct; 32(5):713-21. PubMed ID: 23587733
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Gut hormones in the treatment of short-bowel syndrome and intestinal failure.
    Jeppesen PB
    Curr Opin Endocrinol Diabetes Obes; 2015 Feb; 22(1):14-20. PubMed ID: 25485516
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Teduglutide: a guide to its use in short bowel syndrome.
    McKeage K
    Clin Drug Investig; 2015 May; 35(5):335-40. PubMed ID: 25859983
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Short bowel syndrome. GLP-2 analog teduglutide].
    Storr M
    Med Monatsschr Pharm; 2013 Sep; 36(9):343-5. PubMed ID: 24069647
    [No Abstract]   [Full Text] [Related]  

  • 15. Advances in glucagon like peptide-2 therapy. physiology, current indications and future directions.
    Sigalet DL
    Semin Pediatr Surg; 2018 Aug; 27(4):237-241. PubMed ID: 30342598
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Teduglutide enhances structural adaptation of the small intestinal mucosa in patients with short bowel syndrome.
    Tappenden KA; Edelman J; Joelsson B
    J Clin Gastroenterol; 2013 Aug; 47(7):602-7. PubMed ID: 23426461
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Increased intestinal absorption in the era of teduglutide and its impact on management strategies in patients with short bowel syndrome-associated intestinal failure.
    Seidner DL; Schwartz LK; Winkler MF; Jeejeebhoy K; Boullata JI; Tappenden KA
    JPEN J Parenter Enteral Nutr; 2013 Mar; 37(2):201-11. PubMed ID: 23343999
    [TBL] [Abstract][Full Text] [Related]  

  • 18. GLP-2 analog Teduglutide in active Crohn's disease and short bowel syndrome: Confirmation of anti-inflammatory role and future perspectives.
    Borghini R; Caronna R; Donato G; Picarelli A
    Dig Liver Dis; 2020 Jun; 52(6):686-687. PubMed ID: 32340888
    [No Abstract]   [Full Text] [Related]  

  • 19. Teduglutide for treatment of adult patients with short bowel syndrome.
    Billiauws L; Bataille J; Boehm V; Corcos O; Joly F
    Expert Opin Biol Ther; 2017 May; 17(5):623-632. PubMed ID: 28293969
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Gut hormones, and short bowel syndrome: the enigmatic role of glucagon-like peptide-2 in the regulation of intestinal adaptation.
    Martin GR; Beck PL; Sigalet DL
    World J Gastroenterol; 2006 Jul; 12(26):4117-29. PubMed ID: 16830359
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.